What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
Short answer: Merge Labs is a real brain-computer-interface (BCI) research startup publicly introduced on January 15, 2026. OpenAI invested in its seed round, while Sam Altman is involved personally. The company is exploring molecular neural interfaces, ultrasound and AI decoding—not selling a consumer device that literally merges people with machines.
What Merge Labs is
Merge Labs combines neuroscience, bioengineering, molecular biology, ultrasound, device engineering and artificial intelligence. Its stated ambition is to “bridge biological and artificial intelligence” with a neural interface that can exchange far more information than today’s systems while avoiding implants directly into brain tissue.
| # | Preview | Product | Price | |
|---|---|---|---|---|
| 1 |
|
Human-Computer Interface Technologies for the Motor Impaired (Rehabilitation Science in Practice... | $62.39 | Buy on Amazon |
A BCI records or stimulates neural activity and translates it into computer commands. In practical terms, that might mean helping someone with paralysis select letters, control a computer or operate an assistive device. Merge’s broader vision includes two-way interaction between people and AI, but the company has not publicly demonstrated a working human system.
Merge says it is starting as a research lab and expects the hardest problems to take years or decades. As of August 18, 2026, there was no publicly announced Merge product, price, FDA clearance, human clinical-trial enrollment page or consumer purchase route.
#1 Best Overall
Merge Labs’ introduction describes the company’s mission and research direction.
Who is involved
Publicly identified participants include:
- Mikhail Shapiro, a researcher associated with molecular and biological neural interfaces.
- Tyson Aflalo, a neural-engineering researcher.
- Sumner Norman, a neural-engineering researcher and Forest Neurotech co-founder.
- Alex Blania and Sandro Herbig, technology executives associated with Tools for Humanity.
- Sam Altman, participating in a personal capacity.
Reporting has connected Merge Labs with Forest Neurotech, a nonprofit working on ultrasound-based neural interfaces. That corporate history comes from reporting rather than a detailed current first-party filing. WIRED reported on the relationship.
What “merge” means—and what it does not mean
The practical meaning
In the near term, “merge” is best understood as a more direct interface between a person and software. A system could decode constrained, task-specific neural signals—such as an intended cursor movement or attempted speech—and turn them into an action.
The speculative meaning
Altman has used “the merge” for years to describe a future in which biology and machine intelligence become more closely integrated. That language can suggest mind uploading, shared consciousness or superhuman thought, but Merge’s public announcements do not establish any of those capabilities.
Outdated Drivers Are Slowing You Down
One free scan finds every outdated or missing driver and matches the right update for your exact hardware.Free scan · exact hardware matchWindows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallThe company’s material supports an ambitious BCI research program, not an achieved human-machine hybrid or imminent consumer enhancement product. WIRED’s background coverage provides context for Altman’s earlier use of the term.
What Merge Labs says it is trying to build
More bandwidth and broader coverage
Merge says current interfaces need major gains in both bandwidth—the amount of information exchanged per second—and coverage—how much of the brain can be accessed. Those are research goals, not published specifications.
Molecules instead of conventional electrodes
The company has discussed using molecular connections to interact with neurons rather than relying solely on electrode arrays. A molecular approach could, in principle, provide a different way to sense or influence neural activity, but its long-term safety, precision and durability remain to be demonstrated.
Ultrasound for deeper access
Merge also points to ultrasound as a way to transmit or receive information from deeper brain regions without placing an implant into brain tissue. “Less invasive” does not mean risk-free: ultrasound energy, molecular agents, stimulation hardware and neural-data collection each require separate safety testing.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Scan for outdated or missing drivers - takes under a minuteDriver Scan →Repair Windows errors before they cause bigger problemsFix Now →AI that adapts to each user
Neural signals are noisy and vary between individuals. Merge and OpenAI describe AI models that could interpret limited signals, learn a user’s patterns and adapt as those patterns change. An adaptive decoder may improve usability, but it also makes failures harder to attribute: an error could originate in the sensor, the training data, the model or the user’s changing biology.
Potential applications, ranked by maturity
- Assistive communication and device control: The clearest medical case is helping people with paralysis or severe neurological impairment communicate and operate computers or other devices.
- Speech and movement restoration: Translating attempted speech or movement into useful output is plausible but technically and clinically difficult.
- Health and rehabilitation: Neural interfaces might eventually support healthier brain states or rehabilitation, subject to clinical evidence.
- Broader human-AI interaction: A richer connection to AI is a longer-term possibility rather than a demonstrated capability.
- General enhancement or shared consciousness: These remain speculative and are not established by Merge’s public material.
Merge Labs compared with other BCI programs
The meaningful comparison is technical maturity and access route—not simply Altman versus Elon Musk.
| Organization | Approach | Public status and access |
|---|---|---|
| Merge Labs | Research into molecular interfaces, ultrasound and high-bandwidth, less-invasive systems that aim to avoid implants in brain tissue. | Early research lab; no publicly announced commercial product or Merge human-trial registry. |
| Neuralink | Implanted N1 BCI recording neural signals for computer, smartphone and robotic-arm control. | Conducting clinical trials and accepting patient-registry submissions; investigational device. |
| Synchron | Stentrode delivered through a blood vessel via the jugular vein, avoiding open-brain surgery. | Investigational clinical program; not approved for commercial use. |
| BrainGate | Academic and clinical research into neural recording, communication, movement restoration and neuroprosthetics. | Research and clinical-development ecosystem, not a consumer product. |
See the organizations’ current information at Neuralink’s trials page, Neuralink’s device-control description, Synchron, Synchron’s technology page and BrainGate.
Why OpenAI is involved
OpenAI says it invested in Merge Labs and will collaborate on scientific foundation models, AI tools for bioengineering, neuroscience, device engineering and interpretation of noisy neural signals. That could make AI a central part of decoding and operating a BCI.
OpenAI’s announcement does not describe Merge Labs as an OpenAI subsidiary or product. It says Altman is involved personally. The arrangement therefore raises legitimate disclosure and oversight questions because Altman is also OpenAI’s chief executive, but the public information does not establish wrongdoing. OpenAI’s announcement is the primary source for its role.
How much money has Merge raised?
Bloomberg and WIRED reported an approximately $252 million seed round announced in January 2026, with participation reportedly including OpenAI, Bain Capital, Interface Fund, Fifty Years and Valve co-founder Gabe Newell. The figure and investor list should be treated as reported financing details, not as figures disclosed in OpenAI’s announcement. See Bloomberg’s report and WIRED’s report.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.The technical problems that must be solved
- Signal quality: Neural activity is noisy and differs across people.
- Bandwidth and latency: A useful system must transmit enough information quickly and consistently.
- Specificity: It must distinguish intended actions from unrelated brain activity.
- Stability: Performance must survive changes in biology, hardware and user behavior.
- Calibration: Individual users may need extensive training and continued adaptation.
- Bidirectional communication: Safely reading signals is different from writing information back into the brain.
- Biocompatibility and energy: Materials, molecules, ultrasound and stimulation must remain safe over time.
- Manufacturing: A laboratory technique must become repeatable, scalable and affordable.
- Clinical validation: Benefits must be shown in controlled human studies before medical use.
- Security and privacy: Neural data and stimulation systems could become targets for misuse.
Medical, regulatory and privacy realities
A BCI intended to treat paralysis or restore communication is a medical device, not an ordinary consumer gadget. A laboratory demonstration does not equal regulatory clearance, insurance coverage, clinical availability or retail purchaseability.
Synchron says its system is investigational and not approved for commercial use in any geography (official site). Neuralink describes its N1 program as an investigational clinical trial (device-control trial). BrainGate presents itself as a research and clinical-development collaboration (official site).
Any eventual system would also need rules for ownership of raw neural recordings and AI-derived interpretations, informed consent, cybersecurity, model errors and the boundary between medical restoration and elective enhancement. More neural bandwidth could improve usefulness while increasing the sensitivity of the information collected.
Can you buy Merge Labs technology or join a trial?
No public Merge Labs purchase page, price or patient registry has been announced. Its public material invites people interested in contributing to contact the team, but it does not offer a consumer product or guaranteed treatment.
People seeking legitimate BCI research opportunities should use official trial information only:
- Neuralink’s trial and patient-registry pages list investigational studies. Eligibility is limited; one device-control description focuses on adults with severe hand-function limitations caused by spinal-cord injury or ALS, among other criteria.
- Synchron’s trial-interest page provides a route to inquire about studies. The device remains investigational.
- BrainGate participation depends on specific studies and clinical eligibility.
None of these routes is an ordinary retail purchase, and no company listed here currently offers a mainstream consumer “human-AI merge” device.
Recommended Free Tools
Bottom line
Merge Labs is a genuine, heavily funded BCI research venture with an unusually ambitious goal: achieve useful neural communication with less invasive methods and AI assistance. Its public record currently shows a mission, proposed technologies and investment—not a demonstrated human system, approved treatment or product anyone can buy. The central test will be whether molecular interfaces and ultrasound can deliver reliable, high-bandwidth performance without trading away safety, privacy or clinical accountability.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
